339 related articles for article (PubMed ID: 17573299)
1. Nurses' guide to understanding and implementing the National Comprehensive Cancer Network guidelines for myeloid growth factors.
Wilson BJ; Gardner AE
Oncol Nurs Forum; 2007 Mar; 34(2):347-53. PubMed ID: 17573299
[TBL] [Abstract][Full Text] [Related]
2. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
Kearney N; Friese C
Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
[TBL] [Abstract][Full Text] [Related]
3. Oncology nurses' use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia.
Nirenberg A; Reame NK; Cato KD; Larson EL
Oncol Nurs Forum; 2010 Nov; 37(6):765-73. PubMed ID: 21059588
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte colony-stimulating factors: finding the right indication.
Lyman GH; Shayne M
Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
[TBL] [Abstract][Full Text] [Related]
5. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
Donohue R
Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450
[TBL] [Abstract][Full Text] [Related]
6. Neutropenia: state of the knowledge part I.
Nirenberg A; Bush AP; Davis A; Friese CR; Gillespie TW; Rice RD
Oncol Nurs Forum; 2006 Nov; 33(6):1193-201. PubMed ID: 17149402
[TBL] [Abstract][Full Text] [Related]
7. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
Daniel DB; Crawford J;
Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
[TBL] [Abstract][Full Text] [Related]
8. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
Lyman GH; Kleiner JM
Cancer Treat Res; 2011; 157():145-65. PubMed ID: 21052955
[TBL] [Abstract][Full Text] [Related]
9. NCCN guidelines advocate wider use of colony-stimulating factor.
McNeil C
J Natl Cancer Inst; 2005 May; 97(10):710-1. PubMed ID: 15900037
[No Abstract] [Full Text] [Related]
10. Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia.
Cappozzo C
Oncol Nurs Forum; 2004 May; 31(3):569-76. PubMed ID: 15146222
[TBL] [Abstract][Full Text] [Related]
11. Neutropenia management with granulocyte colony-stimulating factors: from guidelines to nursing practice protocols.
Dolan S; Crombez P; Munoz M
Eur J Oncol Nurs; 2005; 9 Suppl 1():S14-23. PubMed ID: 16207534
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy dose and dose intensity: analyzing data to guide therapeutic decisions.
Gillespie TW
Oncol Nurs Forum; 2001 Mar; 28(2 Suppl):5-10. PubMed ID: 11291209
[TBL] [Abstract][Full Text] [Related]
13. Assessment of neutropenia-related quality of life in a clinical setting.
Ropka ME; Padilla G
Oncol Nurs Forum; 2007 Mar; 34(2):403-9. PubMed ID: 17573304
[TBL] [Abstract][Full Text] [Related]
14. Analyzing current practice patterns: lessons from Amgen's Project ChemoInsight.
Hayes NA
Oncol Nurs Forum; 2001 Mar; 28(2 Suppl):11-6. PubMed ID: 11291207
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
16. Neutropenia: state of the knowledge part II.
Nirenberg A; Parry Bush A; Davis A; Friese CR; Wicklin Gillespie T; Rice RD
Oncol Nurs Forum; 2006 Nov; 33(6):1202-8. PubMed ID: 17149403
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
Crawford J; Dale DC; Lyman GH
Cancer; 2004 Jan; 100(2):228-37. PubMed ID: 14716755
[TBL] [Abstract][Full Text] [Related]
18. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M; Ganser A; Bokemeyer C; ; ;
Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
[TBL] [Abstract][Full Text] [Related]
19. Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk.
Sauerland C; Engelking C; Wickham R; Corbi D
Oncol Nurs Forum; 2006 Nov; 33(6):1134-41. PubMed ID: 17149396
[TBL] [Abstract][Full Text] [Related]
20. The importance of assessment rating scales for chemotherapy-induced oral mucositis.
Jaroneski LA
Oncol Nurs Forum; 2006 Nov; 33(6):1085-90; quiz 1091-3. PubMed ID: 17149392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
